• About us
    • Profile
    • Board of Directors
    • Research Leadership
  • Our Science
    • Strategy
    • Activities and Technologies
    • Publications
  • Pipeline
    • Pipeline
    • 68Ga-OncoFAP (Imaging)
    • 18F-OncoFAP (Imaging)
    • 177Lu-OncoFAP-23 (Therapy)
    • OncoFAP-GlyPro-MMAE (Therapy)
    • 68Ga-OncoACP3 (Imaging)
    • 18F-OncoACP3 (Imaging)
    • 177Lu-OncoACP3 (Therapy)
    • 225Ac-OncoACP3 (Therapy)
    • 68Ga-OncoCAIX (Imaging)
    • 177Lu-OncoCAIX (Therapy)
  • Press Release & Media
    • Press Releases
    • Events
    • Media Library
  • Work with us
    • Careers
    • Industrial Ph.D. Program
    • Partnering & Fee-For-Services
  • About us
    • Profile
    • Board of Directors
    • Research Leadership
  • Our Science
    • Strategy
    • Activities and Technologies
    • Publications
  • Pipeline
    • Pipeline
    • 68Ga-OncoFAP (Imaging)
    • 18F-OncoFAP (Imaging)
    • 177Lu-OncoFAP-23 (Therapy)
    • OncoFAP-GlyPro-MMAE (Therapy)
    • 68Ga-OncoACP3 (Imaging)
    • 18F-OncoACP3 (Imaging)
    • 177Lu-OncoACP3 (Therapy)
    • 225Ac-OncoACP3 (Therapy)
    • 68Ga-OncoCAIX (Imaging)
    • 177Lu-OncoCAIX (Therapy)
  • Press Release & Media
    • Press Releases
    • Events
    • Media Library
  • Work with us
    • Careers
    • Industrial Ph.D. Program
    • Partnering & Fee-For-Services

Philogen to present at the CEO Roundtable Zoom Session organised by Goldman Sachs in June, 2021

by last | Jun 8, 2021 | 2021, Past Events

Philogen announces its participation at the CEO Roundtable Zoom Session organised by Goldman Sachs from June 8 to 29, 2021. Co-founder, CEO and CSO, Prof. Dario Neri has been invited to share and discuss all the dimensions of the unprecedented current market...

Philogen to participate at the BIO Digital 2021 on June 14-18, 2021

by last | Jun 8, 2021 | 2021, Past Events

Philogen participates at the BIO Digital 2021, the international partnering event in the life science and pharma industry, on June 14-18, 2021. Please meet with us in case you are interested in a collaboration or partnership with the Philogen Group.

Philogen S.p.A. announces its maiden First Quarter 2021 Results on Wednesday 12th May 2021

by last | May 12, 2021 | 2021, Past Events

A virtual briefing was hosted for sell-side analysts at 9:00am EST / 14:00pm BST / 15:00pm CEST on Thursday 13th May 2021. PRESS RELEASE – 6-05-2021

Philogen will be attending the PEGS Boston Virtual Summit

by last | May 11, 2021 | 2021, Past Events

Philogen will be attending the PEGS Boston Virtual Summit from May 11th to 13th, 2021. Alessandra Villa, Head of Antibody Research will give a lecture with the title “Targeted Immunocytokines” on May 12th. Samuele Cazzamalli, Head of Small Molecule Therapeutics will...

Philogen announces its intention to float on the Mercato Telematico Azionario organised and managed by Borsa Italiana S.P.A

by last | Feb 1, 2021 | 2021, Past Events

Next Entries »

Recent Posts

  • 2026 Swiss Chemical Society (SCS) Industrial Science Award for Samuele Cazzamalli, Head of Research at Philochem
  • Philochem to attend the Festival of Biologics 2025 in Basel on September 30-October 2, 2025
  • Philochem AG Announces Completion of Antitrust Clearance and Closing of the OncoACP3 Licensing Agreement with RayzeBio, a Bristol Myers Squibb Company, With a Potential Value of up to $1.35 Billion Plus Royalties
  • Philogen is pleased to invite you to a webinar with Prof. Dario Neri, taking place today, June 11, at 11:00 ET | 17:00 CET.
  • Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties.
Privacy Policy / Cookie Policy

Contacts

  • Follow

Philochem AG | Libernstrasse 3 | CH-8112 | Otelfingen – Switzerand |MWST-Nr/VAT-REG: CHE-113.181.443 | Registration Nr. CH-020.3.030.226-7 Ph. (+41) 43 544 88 00 | Fax (+41) 43 544 88 09| info@philochem.ch